Brief: Nicox Expects Significant Milestones In 2021

Nicox SA

05/01/2021 06:42

Jan 5 (Reuters) - Nicox SA  NCOX.PA :
    * WE EXPECT SIGNIFICANT MILESTONES IN 2021, ABOVE ALL RESULTS FROM
LATE-STAGE
CLINICAL TRIALS WITH OUR LEAD ASSETS NCX 470 AND NCX 4251
    * TOP-LINE RESULTS ARE CURRENTLY EXPECTED IN Q4 2021 FOR MONT BLANC AND IN
Q4 2022
FOR DENALI
    * WE DO NOT CURRENTLY ANTICIPATE DELAYS IN OUR CLINICAL TIMELINES 

Source text for Eikon:  ID:nGNE9lgZRm 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))